Floatz logo

64 assets in Esophageal Squamous Cell Carcinoma

Therapeutic assets addressing Esophageal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Esophageal Squamous Cell Carcinoma
AstraZenecaP3BB (66)
Irinotecan
Esophageal Squamous Cell Carcinoma
Taiho Oncology, Inc.P2BB (64)
Levofolinic Acid
Esophageal Squamous Cell Carcinoma
Taiho Oncology, Inc.P3BB (64)
Cetuximab
Esophageal Squamous Cell Carcinoma
Hummingbird BioscienceP2B (63)
Oxaliplatin
Esophageal Squamous Cell Carcinoma
Taiho Oncology, Inc.P3B (63)
Pembrolizumab
Esophageal Squamous Cell Carcinoma
GV20 TherapeuticsP3B (62)
Cis-Diamminedichloroplatinum Ii
Esophageal Squamous Cell Carcinoma
AstraZenecaP3B (61)
Capecitabine
Esophageal Squamous Cell Carcinoma
Chongqing University Cancer HospitalP2B (60)
Carboplatin
Esophageal Squamous Cell Carcinoma
AstraZenecaP2B (59)
Lenvatinib
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP3B (59)
Nivolumab
Esophageal Squamous Cell Carcinoma
Mayo ClinicP2B (57)
Fluzoparib
Esophageal Squamous Cell Carcinoma
Chongqing University Cancer HospitalP2CCC (53)
Serplulimab
Esophageal Squamous Cell Carcinoma
RenJi HospitalP2CCC (53)
Surufatinib
Esophageal Squamous Cell Carcinoma
RenJi HospitalP2CCC (53)
Tislelizumab
Esophageal Squamous Cell Carcinoma
SOLTI Breast Cancer Research GroupP2CCC (53)
Favezelimab
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP1/2CCC (52)
Sinoporphyrin Sodium
Esophageal Squamous Cell Carcinoma
Peking UniversityP2CCC (51)
Futibatinib
Esophageal Squamous Cell Carcinoma
Taiho Oncology, Inc.P2CCC (50)
Spartalizumab
Esophageal Squamous Cell Carcinoma
SOLTI Breast Cancer Research GroupP2CCC (50)
177lu-betabart
Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, LtdP1/2CCC (48)
ap203
Esophageal Squamous Cell Carcinoma
AP Biosciences Inc.P1/2CCC (48)
Chadox1-Magea3-Nyeso
Esophageal Squamous Cell Carcinoma
Cancer Research UKP1/2CCC (48)
Docetaxel
Esophageal Squamous Cell Carcinoma
Hummingbird BioscienceP1/2CCC (48)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Esophageal Squamous Cell Carcinoma
Hummingbird BioscienceP1/2CCC (48)
Idp-001
Esophageal Squamous Cell Carcinoma
InduPro, Inc.P1/2CCC (48)
Mva-Magea3
Esophageal Squamous Cell Carcinoma
Cancer Research UKP1/2CCC (48)
Mva-Nyeso
Esophageal Squamous Cell Carcinoma
Cancer Research UKP1/2CCC (48)
asp0739
Esophageal Squamous Cell Carcinoma
Astellas Pharma Global Development, Inc.P1/2CC (47)
Jab-8263
Esophageal Squamous Cell Carcinoma
Jacobio Pharmaceuticals Co., Ltd.P1/2CC (47)
mk-4830
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP1/2CC (46)
Ale.P02
Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AGP1/2CC (43)
alx2004
Esophageal Squamous Cell Carcinoma
ALX Oncology Inc.P1CC (43)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Esophageal Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CC (43)
Dexasone
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Fulvestrant
Esophageal Squamous Cell Carcinoma
Terremoto Biosciences Inc.P1/2CC (43)
ide892
Esophageal Squamous Cell Carcinoma
IDEAYA BiosciencesP1CC (43)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific
Esophageal Squamous Cell Carcinoma
Merus B.V.P1/2CC (43)
Ipilimumab
Esophageal Squamous Cell Carcinoma
Neonc Technologies, Inc.P1/2CC (43)
LY3143921
Esophageal Squamous Cell Carcinoma
Cancer Research UKP1CC (43)
MAT2A-IN-9
Esophageal Squamous Cell Carcinoma
IDEAYA BiosciencesP1CC (43)
MGC026
Esophageal Squamous Cell Carcinoma
MacroGenicsP1CC (43)
neo212
Esophageal Squamous Cell Carcinoma
Neonc Technologies, Inc.P1/2CC (43)
Nrm-823
Esophageal Squamous Cell Carcinoma
Normunity AccelCo, Inc.P1CC (43)
Osimertinib
Esophageal Squamous Cell Carcinoma
Merus B.V.P1/2CC (43)
Regorafenib
Esophageal Squamous Cell Carcinoma
Neonc Technologies, Inc.P1/2CC (43)
Rndo-564
Esophageal Squamous Cell Carcinoma
Rondo TherapeuticsP1CC (43)
Sacituzumab Tirumotecan
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP1/2CC (43)
Ter-2013
Esophageal Squamous Cell Carcinoma
Terremoto Biosciences Inc.P1/2CC (43)
Tobemstomig
Esophageal Squamous Cell Carcinoma
Hoffmann-La RocheP1/2CC (43)
xb010
Esophageal Squamous Cell Carcinoma
ExelixisP1CC (43)
Showing 1 to 50 of 64 assets
PreviousPage 1 of 2Next